Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q1 EPS of ($0.25), $0.11 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $79.86 million versus the consensus estimate of $76.97 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2024 revenue of $370-390 million, versus the consensus of $383 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Anthropic delays planned IPO from October to November - WSJ